Genetics of Cytochrome CYP2D6 and Effects of Codeine and Tramadol on Postoperative Pain Management (CYP2D6)

A Genetic Survey of Cytochrome P450 2D6 Genotypes by Nanopore DNA Sequencing and Clinical Response to Codeine and Tramadol in Postoperative Pain Management

Codeine is one of the most commonly prescribed opioids in the world. The speed at which our liver metabolizes codeine into morphine depends on an important protein called cytochrome P450 2D6 (CYP2D6). Many people across the world have different CYP2D6 metabolizing speeds. Codeine provides inadequate pain management to those who have slow-metabolizing CYP2D6. In contrast, codeine can be life-threatening to those who have rapidly-metabolizing CYP2D6 because of the abruptly high dose of morphine. By analyzing specific genes, we are able to predict a patient's response to medication, thus drug type and dosing can be tailored according to their genetics. The purpose of this study is to observe if nanopore CYP2D6 DNA genetic sequencing can classify patients according to their CYP2D6 phenotype and thus predict their response to codeine and tramadol. The overall project is to determine the practicality of a genetic survey of CYP2D6 for healthy patients undergoing surgical procedures.

Study Overview

• Status: Completed
• Conditions: Post-operative Pain

Detailed Description

PURPOSE: The purpose of this study is to investigate if genetic variants of CYP2D6 are a predictive factor for postoperative pain management with conventional codeine and tramadol pain therapy. With CYP2D6 DNA analysis, we hope to be able to correlate a patients' genetics and their physiological response to conventional codeine and tramadol dosing.

RESEARCH QUESTION: Is CYP2D6 metabolizer status a predictive factor for the effectiveness of postoperative pain management with conventional pain therapy doses of codeine and tramadol?

HYPOTHESIS: Our hypothesis is that patients with known rapid metabolizing CYP2D6 variants will have higher incidences of opioid side effects with conventional opioid dosing. On the other hand, patients with known poor-metabolizing CYP2D6 variants will have inadequate pain management with conventional opioid dosing.

JUSTIFICATION: Understanding the relationship between CYP2D6 variants and conventional opioid dosing in a clinical setting will facilitate future studies that investigate personalized dosing in order to improve pain management and reduce risk of opioid side effects.

OBJECTIVES: The primary objective of this study is to determine the practicality of undertaking a medium-scale genetic survey of CYP2D6 for healthy patients undergoing surgical procedures. Secondary objectives include: investigate the feasibility of characterizing CYP2D6 genetic variants into one of four metabolizer groups, investigate if there is a distinguishable pattern between CYP2D6 metabolizer status and postoperative pain management quality with conventional pain therapy dosages such as codeine and tramadol, investigate if there is a distinguishable pattern between CYP2D6 metabolizer status and the presence of opioid side effects with conventional pain therapy dosages such as codeine and tramadol, to raise awareness of the clinical relevance of CYP2D6 variants on codeine and tramadol metabolism as well as the complications that arise from conventional, non-personalized pain management.

RESEARCH DESIGN: Prospective observational feasibility study of healthy elective surgical patients. Projected enrolment up to 50 participants. All participants receive standardized anesthetic with weight based dosing of opiates. Data collected will include: 2-3 ml blood sample taken prior to surgery under general anesthesia, DNA sequencing and genotype identification, chart review during post-operative care unit stay (PACU), and a survey administered by phone 24 after discharge from the PACU.

STATISTICAL ANALYSIS: Given the exploratory nature of this feasibility study and small convenience sample size, data will be summarized using descriptive statistics for most outcome variables. If possible, nonparametric statistical tests may be performed to look at associations between genetic variant and outcomes and differences between the groups.

• Study Type: Observational
• Enrollment (Actual): 22

Contacts and Locations

Study Locations

• Canada
  • British Columbia
    • New Westminster, British Columbia, Canada, V3L 3W7
      • Royal Columbian Hospital

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: Adult
• Accepts Healthy Volunteers: Yes

• Sampling Method: Non-Probability Sample

Study Population

For the pilot study, healthy patients (ASA 1 or 2) who are undergoing surgical procedures at Royal Columbian Hospital or Eagle Ridge Hospital with projected moderate postoperative pain will be selected. It is estimated that five patients will be approached to learn more about the study each week and 50-60% will consent to participate given the minimally invasive study procedures and the potential for participants to learn valuable personal pain medication metabolizing genetic status. Therefore, this study aims to enroll approximately ten patients per month up to a maximum of fifty total patients over a five-month span.

Description

Inclusion Criteria:

1. Age 18-55 year and otherwise healthy (ASA 1 or 2)
2. Undergoing an elective outpatient surgical procedure at Royal Columbian Hospital or Eagle Ridge Hospital with projected moderate post-operative pain
3. Surgical procedure that requires general anaesthetic and post-operative pain management routinely managed with either codeine or tramadol by attending surgeon (i.e., ACL repair)
4. Attending surgeon routinely prescribes either tramadol or codeine for post-operative pain management

Exclusion Criteria:

1. Pre-existing chronic pain condition
2. Any psychiatric diagnosis, such as depression or anxiety (Lautenbacher et al., 1994)
3. History of substance abuse/dependence
4. Multiple medical comorbidities (a single well-controlled medical comorbidity will not be a contraindication - i.e., controlled hypothyroidism)
5. Allergy, sensitivity, or other contraindication to either codeine or tramadol
6. Regional anesthetic (inclusive either of a major peripheral nerve block or neuraxial anesthetic) planned by attending anesthesiologist)
7. Unable to provide informed consent

Study Plan

How is the study designed?

Number of groups / cohorts

1

Cohorts and Interventions

Group / Cohort
Healthy surgical patients; Healthy surgical patients who are undergoing surgical procedures with projected moderate postoperative pain.

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
CYP2D6 genotypes/phenotypes	CYP2D6 genotype determined by nanopore DNA sequencing which will be cross-referenced with published genotypes to determine CYP2D6 phenotype	6 months

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Total opiate consumption	Total opiate consumption (morphine milligram equivalents, continuous) observed immediately post-op, before tramadol or codeine administration, and 1 hour or later post tramadol/codeine administration	6 months
Pain scores	Pain scores (0 - 10, ordinal) observed immediately post-op, before tramadol or codeine administration, and 1 hour or later post tramadol/codeine administration	6 months
Sedation level	Sedation assessments (1 - 4, ordinal) observed immediately post-op, before tramadol or codeine administration, and 1 hour or later post tramadol/codeine administration	6 months
Administration of anti-nausea medications	Administration of anti-nausea medications (Yes/No, dichotomous) observed immediately post-op, before tramadol or codeine administration, and 1 hour or later post tramadol/codeine administration	6 months
Postoperative Day 1 current pain and worst pain since discharge	Current pain and worst pain since discharge (0 - 10, ordinal) at 24-hour post-op discharge telephone follow-up call	6 months
Postoperative Day 1 Nausea and vomiting (Yes/No, dichotomous)	Nausea and vomiting (Yes/No, dichotomous) at 24-hour post-op discharge telephone follow-up call.	6 months
Total opioids taken since discharge	Total opioids taken since discharge (morphine milligram equivalents, continuous) at 24-hour post-op discharge telephone follow-up call.	6 months

Collaborators and Investigators

• Sponsor: Fraser Health
• Collaborators: University of British Columbia
• Investigators: Principal Investigator: Perseus Missirlis, MSc, MD, Fraser Health

Study record dates

Study Major Dates

• Study Start (Actual): November 25, 2022
• Primary Completion (Actual): July 10, 2024
• Study Completion (Actual): December 1, 2024

Study Registration Dates

• First Submitted: December 4, 2024
• First Submitted That Met QC Criteria: December 4, 2024
• First Posted (Estimated): December 9, 2024

Study Record Updates

• Last Update Posted (Estimated): December 9, 2024
• Last Update Submitted That Met QC Criteria: December 4, 2024
• Last Verified: December 1, 2024

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Pain; Neurologic Manifestations; Postoperative Complications; Pathologic Processes; Pain, Postoperative
• Other Study ID Numbers: 21-01422

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: NO

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No
• product manufactured in and exported from the U.S.: No